Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk
Background and Purpose: Type 1 diabetes is a chronic autoimmune disease from the group of metabolic disorders, where the immune system attacks and destroys the insulin producing cells of the pancreas, leading to hyperglycemia and the need for lifelong exogenous insulin supplementation. This results...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2023-08-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/45204 |
| _version_ | 1797740934587219968 |
|---|---|
| author | Justyna Białek Karolina Nitka Marta Więckowska-Deroń Monika Leszcz Dominika Ćwik-Błotnicka Joanna Borczyk Martyna Lewkowicz |
| author_facet | Justyna Białek Karolina Nitka Marta Więckowska-Deroń Monika Leszcz Dominika Ćwik-Błotnicka Joanna Borczyk Martyna Lewkowicz |
| author_sort | Justyna Białek |
| collection | DOAJ |
| description |
Background and Purpose: Type 1 diabetes is a chronic autoimmune disease from the group of metabolic disorders, where the immune system attacks and destroys the insulin producing cells of the pancreas, leading to hyperglycemia and the need for lifelong exogenous insulin supplementation. This results in increased morbidity, life threatening complications, shortened lifespan and quality of life. So there is an urgent need to develop prevention and treatment for people at risk of developing type 1 diabetes.
Current state of knowledge: Recently, there has been significant progress in the field of immunotherapy with therapeutic strategies that focus on stopping the disease in the presymptomatic stage by preserving residual beta-cell function. Randomized, double-blind clinical trials of teplizumab were conducted in relatives of patients with established type 1 diabetes who had not yet been diagnosed with the disease, but were at high risk of developing clinical disease, based on these studies The FDA has approved teplizumab, under trade name Tzield, as a treatment to delay the onset of type 1 diabetes.
Conclusion: The reviewed research papers present strong evidence that teplizumab halts the severe decline in beta cells and possibly improves their function after treatment in a high-risk population. In addition, the effect persists.
|
| first_indexed | 2024-03-12T14:19:36Z |
| format | Article |
| id | doaj.art-7f1353994f5a48c3acf543ea58a1bf44 |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-03-12T14:19:36Z |
| publishDate | 2023-08-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-7f1353994f5a48c3acf543ea58a1bf442023-08-19T10:48:24ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062023-08-0144110.12775/JEHS.2023.44.01.018Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at riskJustyna Białek0Karolina Nitka1Marta Więckowska-Deroń2Monika Leszcz3Dominika Ćwik-Błotnicka4Joanna Borczyk5Martyna Lewkowicz6Kliniczny Szpital Wojewódzki Nr 2 im. Św. Jadwigi Królowej w RzeszowieSpecjalistyczny Publiczny Szpital Kliniczny nr 1 w Lublinie, PolskaSamodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, PolskaSamodzielny Publiczny Zakład Opieki Zdrowotnej w Radzyniu Podlaskim, PolskaWojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie, PolskaSzpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Polska4th Department of Internal Medicine, Lower Silesian Oncology, Pulmonology and Hematology Center in Wroclaw, Poland Background and Purpose: Type 1 diabetes is a chronic autoimmune disease from the group of metabolic disorders, where the immune system attacks and destroys the insulin producing cells of the pancreas, leading to hyperglycemia and the need for lifelong exogenous insulin supplementation. This results in increased morbidity, life threatening complications, shortened lifespan and quality of life. So there is an urgent need to develop prevention and treatment for people at risk of developing type 1 diabetes. Current state of knowledge: Recently, there has been significant progress in the field of immunotherapy with therapeutic strategies that focus on stopping the disease in the presymptomatic stage by preserving residual beta-cell function. Randomized, double-blind clinical trials of teplizumab were conducted in relatives of patients with established type 1 diabetes who had not yet been diagnosed with the disease, but were at high risk of developing clinical disease, based on these studies The FDA has approved teplizumab, under trade name Tzield, as a treatment to delay the onset of type 1 diabetes. Conclusion: The reviewed research papers present strong evidence that teplizumab halts the severe decline in beta cells and possibly improves their function after treatment in a high-risk population. In addition, the effect persists. https://apcz.umk.pl/JEHS/article/view/45204teplizumabtype I diabetes |
| spellingShingle | Justyna Białek Karolina Nitka Marta Więckowska-Deroń Monika Leszcz Dominika Ćwik-Błotnicka Joanna Borczyk Martyna Lewkowicz Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk Journal of Education, Health and Sport teplizumab type I diabetes |
| title | Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk |
| title_full | Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk |
| title_fullStr | Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk |
| title_full_unstemmed | Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk |
| title_short | Teplizumab - current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk |
| title_sort | teplizumab current state of knowledge on the effects of teplizumab in preventing the development of type 1 diabetes in people at risk |
| topic | teplizumab type I diabetes |
| url | https://apcz.umk.pl/JEHS/article/view/45204 |
| work_keys_str_mv | AT justynabiałek teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk AT karolinanitka teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk AT martawieckowskaderon teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk AT monikaleszcz teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk AT dominikacwikbłotnicka teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk AT joannaborczyk teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk AT martynalewkowicz teplizumabcurrentstateofknowledgeontheeffectsofteplizumabinpreventingthedevelopmentoftype1diabetesinpeopleatrisk |